Navigation Links
Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Date:9/11/2007

LOS ANGELES, Sept. 11 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Tapestry Pharmaceuticals (Nasdaq: TPPH). Ross Silver, Director of Research for Vista Partners stated, "Tapestry's lead compound TPI-287 showed promise in Phase I trials. We were particularly encouraged by activity in patients with pancreatic cancer as no other taxanes have been approved for use in this difficult to treat cancer." Vista Partners provides independent equity research for institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report; please visit the Vista Partners website at http://www.vistap.com.

Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. For more information about Tapestry and its technologies, visit Tapestry's website at http://www.tapestrypharma.com.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Evista Not A Cure For Heart Disease
2. Spouses and other partners lower blood pressure says new research
3. Changing Partners may put Expectant Mothers at Risk
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. Partnership Between Diabetes India And Elsevier Announced
6. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships
7. Private Public Partnership To Tackle TB, In Karnataka
8. Courting HIV through Marriage or Partnership
9. Jealousy In Men Peaks When Partners Are Most Fertile
10. War Trauma Not Passed On To Partners And Children, Study
11. SRM Inst Signs Mou With Partners Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... Periodontist Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative ... by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a ...
(Date:1/20/2017)... ... ... Source Vitál Apothecary, a skin and body care company dedicated to creating ... a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference in ... nutritional, sports and health industries a chance to meet in private sessions with some ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has ... 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and have ... workout. , After a successful launch in Sweden last year, the next generation ...
(Date:1/20/2017)... ... 2017 , ... “I Forgive You”: a fine examination of how God handles sin, including ... of published author, Stephen Miller, who, for over ten long years has been waiting to ... in Trinidad and Tobago, he has been serving the Lord for over twenty years, and ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
(Date:1/19/2017)... 2017 Report Details ... Alzheimer,s Disease Therapeutics ... – our new study reveals trends, R&D progress, and ... affecting the Alzheimer,s disease therapeutics and diagnostics market. Our ... questions: - How is the Alzheimer,s disease therapeutics and ...
(Date:1/19/2017)... 19, 2017 According to a study conducted ... set to witness a CAGR of 6.5% during the forecast period ... will continue to be the leading market for cryotherapy globally during ... ... on ensuring affordable and adequate supply of gas in order to ...
Breaking Medicine Technology: